Alina S Gerrie

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi request reprint D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma
    Alina S Gerrie
    Hematology, University of British Columbia, Vancouver, BC, Canada
    Br J Haematol 161:802-10. 2013
  2. doi request reprint Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 53:77-82. 2012
  3. doi request reprint Fludarabine and rituximab for relapsed or refractory hairy cell leukemia
    Alina S Gerrie
    Division of Hematology, University of British Columbia, 2775 Laurel St, Vancouver, BC, Canada
    Blood 119:1988-91. 2012
  4. doi request reprint Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, Canada
    Cancer Genet 205:523-7. 2012
  5. doi request reprint IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy
    Patrick C W Wong
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
    Eur J Haematol 90:250-6. 2013

Collaborators

Detail Information

Publications5

  1. doi request reprint D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma
    Alina S Gerrie
    Hematology, University of British Columbia, Vancouver, BC, Canada
    Br J Haematol 161:802-10. 2013
    ..Although the overall response rate of 49% in this poor prognosis cohort is reasonable, the PFS is short, suggesting the best role for D(T)PACE is in bridging to definitive therapy, such as transplantation...
  2. doi request reprint Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 53:77-82. 2012
    ..FR with oral fludarabine was safely, conveniently and successfully given to community-based patients, irrespective of age, for first-line therapy for CLL/SLL, achieving OS and TFS similar to those in clinical trials...
  3. doi request reprint Fludarabine and rituximab for relapsed or refractory hairy cell leukemia
    Alina S Gerrie
    Division of Hematology, University of British Columbia, 2775 Laurel St, Vancouver, BC, Canada
    Blood 119:1988-91. 2012
    ..Five-year progression-free and overall survivals are 89% and 83%, respectively. FR is a safe and effective therapeutic option for relapsed/refractory HCL...
  4. doi request reprint Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, Canada
    Cancer Genet 205:523-7. 2012
    ..Knowledge of the t(IGH@) status in CLL is therefore of clinical importance, as del13q patients with concomitant t(IGH@) may not retain the previously expected favorable outcome...
  5. doi request reprint IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy
    Patrick C W Wong
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
    Eur J Haematol 90:250-6. 2013
    ..Combination therapy with fludarabine and rituximab in IgG4-RD has not previously been reported and can be considered in patients with severe refractory disease...